Filters
Concurrent administration of sacituzumab govitecan and radiotherapy is well tolerated and does not lead to increased toxicity in patients with metastatic breast cancer, a study has shown.
The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).
The incidence of febrile neutropenia (FN) is significantly lesser in children with solid tumours receiving pegylated filgrastim as primary prophylaxis following chemotherapy than in those assigned to filgrastim alone, reports a study. Moreover, no adverse events attributed to the study drug have been observed.
Consumption of ultra-processed food (UPF) does not appear to influence semen quality parameters among men attending a fertility clinic, suggests a study presented at ESHRE 2025.
Pregnancy loss is devastating to any couple, and such an experience may result in depression, stress, and anxiety, particularly among women.
The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).
Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts from the GS-US-216-0128 study presented at IAS 2025.
The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.
Higher esophageal anxiety, use of adaptive behaviours, and hypervigilance are common among patients with active eosinophilic esophagitis (EoE), representing clinical markers of histological disease activity (HDA), a study has found.
Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.
